account_id none on file
legal_name Processa Pharmaceuticals, Inc.
ticker PCSA
cik 1533743
domain processapharmaceuticals.com
linkedin_company_url https://www.linkedin.com/company/processapharma/
entry_point_account_id none on file
name Processa Pharmaceuticals Inc.
exchange Nasdaq
sector Health Care
hq Vero Beach, FL, United States
sector index/company/sector/health-care/
calls 0 filings 3 executives 2 family 0
why_nownone on file
callsnone on file
filings
maintenance expense of $12,000; and travel expenses of $11,000. We received approximately $3,000 more in reimbursements from CorLyst
filing / Aug 14, 2026 / receipt
Skibsted served as CFO of BioTime, a publicly traded biotechnology company now named Lineage Cell Therapeutics, where he also was
filing / Jun 18, 2026 / receipt
as “householding” and can result in significant cost savings to the Company. To take advantage of this opportunity, we have
filing / Jun 18, 2026 / receipt
executives
| Heather Kearns | Interim Chief Executive Officer | - | receipt |
| John P. McGrain | Interim Chief Executive Officer | - | receipt |
familynone on file
upcoming
| 2026-11-05 | earnings call | scheduled | ir |
changes
| 2024-07-17 | Chief Financial Officer, departed | sec_8k |
| 2023-08-08 | Chief Operating Officer, departed | sec_8k |
| 2020-10-13 | Chief Operating Officer, appointed | sec_8k |
| 2018-09-10 | Chief Financial Officer, appointed | sec_8k |
| 2015-09-17 | director, departed | sec_8k |
| 2015-09-17 | Interim Chief Executive Officer, appointed | sec_8k |
| 2015-09-14 | Interim Chief Executive Officer, appointed | sec_8k |
| 2015-09-04 | director, departed | sec_8k |
| 2015-08-06 | director, departed | sec_8k |
| 2015-06-02 | director, departed | sec_8k |
| 2015-05-06 | Interim Chief Executive Officer, appointed | sec_8k |
| 2015-03-24 | director, departed | sec_8k |
mcp_package_hint
slug processa-pharmaceuticals-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$